Vect-Horus

Harnessing TfR1 for Cross-Species Systemic Delivery of siRNAs to Deep Brain Regions Using Single-Domain Antibodies

Emmanuelle BETTENDORF — 2026-05-26T08:02:28Z

Our latest preprint demonstrating the ability of the VECTrans® platform to deliver therapeutics, particularly oligonucleotides, to deep regions of the brain at clinically viable doses has just been published by bioRxiv.

The research by @Guillaume Jacquot and the Vect-Horus team details the unique functions of our technology platform to transport oligonucleotides across the blood-brain barrier and open up new avenues for the treatment of diverse central nervous system disorders.

“Harnessing TfR1 for Cross-Species Systemic Delivery of siRNAs to Deep Brain Regions Using Single-Domain Antibodies”

Vect-Horus appoints Claudia Fromond as new Director of R&D

Emmanuelle BETTENDORF — 2026-03-10T08:10:40Z

We are very pleased to welcome Claudia Fromond to Vect-Horus as our new Director of R&D.

Claudia is a highly regarded pharmacology and translational science leader with extensive experience in R&D. She has successfully overseen first-in-class programs from discovery to Investigational New Drug (IND) application and early clinical development, including a portfolio of seven IND-enabling programs which achieved Phase 1/2 readiness.

“Claudia has a proven track record of successfully managing R&D projects and shaping R&D strategy across numerous modalities. I am confident that her expertise and vision will be key to advancing our technology and expanding our external collaborations,” said Alexandre Tokay, co-founder and CEO of Vect-Horus.

Meet Vect-Horus at Deeptech in Glioblastoma Symposium

Emmanuelle BETTENDORF — 2026-01-13T09:02:03Z

Cédric Malicet, our Oncology Program Director, will be taking part in a panel discussion at the DeepTech in Glioblastoma conference, organized by Paris Saclay Cancer Cluster (PSCC), and taking place January 22 in Villejuif, France.

Cedric will participate in a pitch session entitled “A comprehensive and diverse front against glioblastoma”, along with representatives from Carthera, TheraSonic, Robeauté, Innov'nCare , with the discussion moderated by Professor Ahmed Idbaih .

It takes place during the first session at 9:30am CET.

We look forward to seeing you there!
👉 https://lnkd.in/dEEE9W4G

How blood–brain barrier technology is unleashing CNS therapies

Emmanuelle BETTENDORF — 2025-09-19T13:52:41Z

Nature Research has republished an in-depth article on Vect-Horus in the September issue of Biopharma Dealmakers. The issue focuses on CNS related technologies and therapeutics.
It's well worth having a read, or re-read, of this piece, which outlines our VECTrans platform and its potential to transform the treatment of neurodegenerative disorders.
It also touches on the science and data behind our approach and our partnerships with Novo Nordisk Radiomedix, Inc. and Ionis Pharmaceuticals, (…)

- News / page_accueil_3_actus, Science

Our latest research article is now available on bioRxiv and medRxiv

Emmanuelle BETTENDORF — 2025-07-11T09:14:41Z

In this study, we explored the identification and optimization of cross-species reactive VHHs (single-domain antibodies from camelids) targeting the transferrin receptor 1 (TfR1) — a promising strategy for delivering therapeutics across the blood-brain barrier.

We focused on two candidates, C5 and B8, which bind TfR1 in rodents, non-human primates, and humans. These VHHs show potential as molecular shuttles for transporting imaging or therapeutic agents across species — paving the way for smoother translation from preclinical to clinical development.

Read the full article: : Identification and optimization of trans-species reactive TfR1-binding VHH as tools for drug delivery across the blood brain barrier

How blood–brain barrier technology is unleashing CNS therapies

Emmanuelle BETTENDORF — 2025-03-18T13:23:19Z

We are proud to be featured in Nature, in an article exploring how we are enabling targeted drug delivery across the blood–brain barrier.

This article highlights the potential of our VECTrans platform, which has the potential to transform the treatment of neurodegenerative disorders. The article goes into the science and data behind our approach as well as our partnerships with Novo Nordisk Radiomedix, Inc. and Ionis Pharmaceuticals, Inc.

Click below for the full article.

👉 https://lnkd.in/d3Pinsy5

mRNA Based Therapeutics poster

Emmanuelle BETTENDORF — 2025-02-03T13:22:20Z

Pavlo Shpak-Kraievskyi is presenting a poster on behalf of Vect-Horus at the 4th Annual mRNA-Based Therapeutics Summit Europe, taking place January 28-30 in Frankfurt, Germany.

Effective delivery of mRNA therapeutics to the central nervous system (CNS) remains a significant challenge due to the protective blood-brain barrier (BBB). The poster, entitled “VECTrans® Technology for CNS Targeting with Lipid Nanoparticles”, outlines results from a study of VECTrans® enabling the targeted delivery of lipid nanoparticles (LNPs) across the BBB using peptide or single-domain antibody (sdAb) vectors.

The results demonstrate enhanced transfection of brain and spinal cord cells an also the precise distribution of LNPs within distinct CNS compartments, including the microvasculature, extracellular fluid (ECF), and parenchyma.

The data underline the capability of this platform to overcome longstanding challenges in CNS-targeted mRNA therapeutics. By enabling precise delivery to challenging targets like the CNS and spinal cord, VECTrans® opens new avenues for treating neurological disorders as well as other diseases requiring targeted and efficient delivery systems.

Vect-Horus Strengthens Board of Directors with Appointment of Jean-Christophe Dantonel as New Member

Emmanuelle BETTENDORF — 2024-11-14T10:06:37Z

We're pleased to welcome Jean-Christophe Dantonel as a new member of the Vect-Horus Board of Directors!

Dr. Dantonel brings over two decades of profound expertise in biological sciences, project management, and clinical research to his new role.

“He brings key skills to our company at an important stage of its development, with a combination of clinical research and business experience which will be invaluable as we innovate to develop vectors that facilitate targeting and delivery of therapeutic and imaging agents to enhance their efficacy,” says Alexandre Tokay, co-founder and CEO of Vect-Horus

Click here for the full press release

Meet Vect-Horus at the 3rd Annual Next Gen Lipid-Based Nanoparticles Delivery Summit, Boston, August 21-23, 2024

Emmanuelle BETTENDORF — 2024-08-21T13:12:18Z

VECT-HORUS S.A.S. will be presenting a poster at the 3rd Annual Next Gen Lipid-Based Nanoparticles Delivery Summit!

This high-profile event is taking place in Boston, MA from August 20-22, and Pavlo Shpak-Kraievskyi, Project leader, is looking forward to attending.

Poster Title: VECTrans® Technology for CNS Targeting by Lipid Nanoparticles

📆 Save the date: 3:30pm ET, Wednesday August 21st
🌐 Learn More: https://ter.li/b5vw3f

Poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting

Emmanuelle BETTENDORF — 2024-05-15T07:03:01Z

The poster, entitled “VECTrans® technology: a powerful delivery approach to significantly enhance efficacy of therapeutic oligonucleotides in retina cells”, outlines a study assessing Vect-Horus' proprietorial VECTrans® technology. This is based on the specific design and optimization of molecular vectors that, once joined to a payload, enable its delivery to target specific organs in the body.

The study showed that these vectors have the potential to improve delivery of medication to the eye. It's a good demonstration of the technology's potential, building further on our two recent major licensing agreements, with Novo Nordisk and Ionis Pharmaceuticals.

With thanks to Stephane Girard, PhD, Ophthalmology Department Manager, and Sebastien Roux, PhD, Neuroscientist, for their work on this.